|
1
|
Shetty M: Imaging and differential
diagnosis of ovarian cancer. Semin Ultrasound CT MR. 40:302–318.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eisenhauer EA: Real-world evidence in the
treatment of ovarian cancer. Ann Oncol. 28 (Suppl_8):viii61–viii65.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang JY, Lu AQ and Chen LJ: LncRNAs in
ovarian cancer. Clin Chim Acta. 490:17–27. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ogunwobi OO and Segura MF: Editorial: PVT1
in Cancer. Front Oncol. 10:5887862020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Guan Y, Kuo WL, Stilwell JL, Takano H,
Lapuk AV, Fridlyand J, Mao JH, Yu M, Miller MA, Santos JL, et al:
Amplification of PVT1 contributes to the pathophysiology of ovarian
and breast cancer. Clin Cancer Res. 13:5745–5755. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang Y, Tan Y, Wang H, Xu M and Xu L:
Long Non-Coding RNA plasmacytoma variant translocation 1 (PVT1)
enhances proliferation, migration, and epithelial-mesenchymal
transition (EMT) of pituitary adenoma cells by activating
β-Catenin, c-Myc, and Cyclin D1 expression. Med Sci Monit.
25:7652–7659. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang Q, Yu Y, Sun Z and Pan Y: Long
non-coding RNA PVT1 promotes cell proliferation and invasion
through regulating miR-133a in ovarian cancer. Biomed Pharmacother.
106:61–67. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kubota S and Takigawa M: Cellular and
molecular actions of CCN2/CTGF and its role under physiological and
pathological conditions. Clin Sci (Lond). 128:181–196. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Arnott JA, Lambi AG, Mundy C, Hendesi H,
Pixley RA, Owen TA, Safadi FF and Popoff SN: The role of connective
tissue growth factor (CTGF/CCN2) in skeletogenesis. Crit Rev
Eukaryot Gene Expr. 21:43–69. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Klaassen I, van Geest RJ, Kuiper EJ, van
Noorden CJ and Schlingemann RO: The role of CTGF in diabetic
retinopathy. Exp Eye Res. 133:37–48. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shen YW, Zhou YD, Chen HZ, Luan X and
Zhang WD: Targeting CTGF in Cancer: An emerging therapeutic
opportunity. Trends Cancer. 7:511–524. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cho SW, Xu J, Sun R, Mumbach MR, Carter
AC, Chen YG, Yost KE, Kim J, He J, Nevins SA, et al: Promoter of
lncRNA Gene PVT1 is a tumor-suppressor DNA boundary element. Cell.
173:1398–1412.e22. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu C, Jin J, Liang D, Gao Z, Zhang Y, Guo
T and He Y: Long Noncoding RNA PVT1 as a novel predictor of
metastasis, clinicopathological characteristics and prognosis in
human cancers: A meta-analysis. Pathol Oncol Res. 25:837–847. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu BQ, Jiang Y, Zhu F, Sun DL and He XZ:
Long noncoding RNA PVT1 promotes EMT and cell proliferation and
migration through downregulating p21 in pancreatic cancer cells.
Technol Cancer Res Treat. 16:819–827. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chang Z, Cui J and Song Y: Long noncoding
RNA PVT1 promotes EMT via mediating microRNA-186 targeting of
Twist1 in prostate cancer. Gene. 654:36–42. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen Y, Du H, Bao L and Liu W: LncRNA PVT1
promotes ovarian cancer progression by silencing miR-214. Cancer
Biol Med. 15:238–250. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zheng J, Hu L, Cheng J, Xu J, Zhong Z,
Yang Y and Yuan Z: lncRNA PVT1 promotes the angiogenesis of
vascular endothelial cell by targeting miR-26b to activate
CTGF/ANGPT2. Int J Mol Med. 42:489–496. 2018.PubMed/NCBI
|
|
19
|
Ding LB, Li Y, Liu GY, Li TH, Li F, Guan J
and Wang HJ: Long non-coding RNA PVT1, a molecular sponge of
miR-26b, is involved in the progression of hyperglycemia-induced
collagen degradation in human chondrocytes by targeting CTGF/TGF-β
signal ways. Innate Immun. 26:204–214. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jiang CG, Lv L, Liu FR, Wang ZN, Na D, Li
F, Li JB, Sun Z and Xu HM: Connective tissue growth factor is a
positive regulator of epithelial-mesenchymal transition and
promotes the adhesion with gastric cancer cells in human peritoneal
mesothelial cells. Cytokine. 61:173–180. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang L, Hou J, Cui XH, Suo LN and Lv YW:
MiR-133b regulates the expression of CTGF in epithelial-mesenchymal
transition of ovarian cancer. Eur Rev Med Pharmacol Sci.
21:5602–5609. 2017.PubMed/NCBI
|
|
22
|
Prieto-García E, Díaz-García CV,
García-Ruiz I and Agulló-Ortuño MT: Epithelial-to-mesenchymal
transition in tumor progression. Med Oncol. 34:1222017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ding Y, Fang Q, Li Y and Wang Y:
Amplification of lncRNA PVT1 promotes ovarian cancer proliferation
by binding to miR-140. Mamm Genome. 30:217–225. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Qu C, Dai C, Guo Y, Qin R and Liu J: Long
non-coding RNA PVT1-mediated miR-543/SERPINI1 axis plays a key role
in the regulatory mechanism of ovarian cancer. Biosci Rep.
40:BSR202008002020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yi K, Hou M, Yuan J, Yang L, Zeng X, Xi M
and Chen J: LncRNA PVT1 epigenetically stabilizes and
post-transcriptionally regulates FOXM1 by acting as a microRNA
sponge and thus promotes malignant behaviors of ovarian cancer
cells. Am J Transl Res. 12:2860–2874. 2020.PubMed/NCBI
|
